Milnacipran Micro Labs (Milnacipran Hydrochloride)

Milnacipran blocks the reuptake of serotonin and norepinephrine by inhibiting their respective transporters. This increases the levels of these neurotransmitters in the brain, enhancing signaling pathways that regulate mood, affect, and pain, thereby providing antidepressant and analgesic effects.

The dosage of Milnacipran is individualized and set by the prescribing clinician based on the patient’s condition, response, and tolerability. Physicians typically start with a low dose and may adjust it gradually, following approved prescribing information and clinical judgment.

Safety data for Milnacipran during pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Compared with selective serotonin reuptake inhibitors (SSRIs), Milnacipran also increases norepinephrine levels, which can provide additional benefit for pain syndromes such as fibromyalgia. Its dual mechanism may result in a different side‑effect profile, including a higher incidence of cardiovascular effects, while offering comparable antidepressant efficacy.

Milnacipran should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and ensure the container is tightly closed to maintain stability throughout its shelf life.

Milnacipran is administered orally, usually as a tablet or capsule. It can be taken with or without food, but patients should follow the prescribing information and take the medication consistently at the same time each day to maintain stable blood levels.

The most serious risks include hypertension, tachycardia, and serotonin syndrome—a potentially life‑threatening condition marked by agitation, hyperreflexia, fever, and rapid heart rate. Patients should seek immediate medical attention if they experience any of these symptoms.

Milnacipran is contraindicated in patients with known hypersensitivity to the drug, those currently taking monoamine oxidase inhibitors, or individuals with uncontrolled severe hypertension. Caution is also advised for patients with hepatic impairment, bipolar disorder, or a history of serotonin syndrome.